Related Experiment Video
Updated: Sep 9, 2025

09:19
Spatial Profiling of Protein and RNA Expression in Tissue: An Approach to Fine-Tune Virtual Microdissection
Published on: July 6, 2022
5.0K
Spatial transcriptomics of retinoblastoma: a visual window on intra-patient heterogeneity
A P Moulin1, J Thevenet2, L Mazzeo3
1Fondation Asile des Aveugles, Jules-Gonin Eye Hospital, Lausanne University, Lausanne, Switzerland. alexandre.moulin@fa2.ch.
BMC Cancer
|September 2, 2025
Summary
This study maps retinoblastoma cell populations, correlating histology with molecular subtypes 1 and 2. It highlights the need for biomarkers to distinguish between retinocytoma and well-differentiated retinoblastoma.
Area of Science:
- Ophthalmology
- Oncology
- Genomics
Background:
- Retinoblastoma is a common childhood eye cancer with variable differentiation and proliferation.
- Molecular subtypes (1 and 2) and intratumoral heterogeneity are known, but spatial mapping is lacking.
- Retinocytoma is a benign, non-proliferative tumor, posing diagnostic challenges.
Purpose of the Study:
- To map retinoblastoma cell populations spatially within a tumor.
- To correlate histological features with molecular subtypes.
- To investigate the diagnostic ambiguity between retinocytoma and retinoblastoma.
Main Methods:
- Spatial transcriptomics on a primary enucleated retinoblastoma with distinct histological areas.
- Analysis of whole transcriptomic profiles from 16 regions of interest.
- Immunohistochemistry for pathway markers and senescence markers.
Main Results:
- Transcriptomic clustering correlated with histological differentiation (highly vs. poorly differentiated).
- Subtypes 1 and 2 molecular signatures mapped perfectly to histological and transcriptomic profiles.
- Senescence marker analysis did not support a retinocytoma diagnosis in the differentiated area.
Conclusions:
- Strong correlation between histology and molecular profiling in retinoblastoma.
- First spatial mapping of adjacent retinoblastoma molecular subtypes 1 and 2.
- Need for specific biomarkers to differentiate retinocytoma from well-differentiated retinoblastoma (subtype 1).

